Emergent Biosolutions (NYSE:EBS) Director Sells $115,592.40 in Stock

Emergent Biosolutions Inc. (NYSE:EBS) Director Sujata Tyagi Dayal sold 13,761 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $115,592.40. Following the sale, the director directly owned 100,563 shares in the company, valued at approximately $844,729.20. The trade was a 12.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Up 0.9%

EBS opened at $9.13 on Thursday. The stock has a market capitalization of $471.72 million, a price-to-earnings ratio of -32.62 and a beta of 2.33. The firm has a 50 day moving average price of $8.46 and a 200-day moving average price of $10.30. Emergent Biosolutions Inc. has a twelve month low of $4.72 and a twelve month high of $14.06. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.46. The business had revenue of $156.10 million during the quarter, compared to the consensus estimate of $145.00 million. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%.

Analyst Ratings Changes

A number of brokerages recently commented on EBS. Wall Street Zen cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, April 27th. Finally, HC Wainwright decreased their target price on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $12.00.

Hedge Funds Weigh In On Emergent Biosolutions

Several institutional investors have recently bought and sold shares of the business. Silver Oak Securities Incorporated bought a new stake in shares of Emergent Biosolutions in the 3rd quarter worth about $941,000. Allianz Asset Management GmbH grew its position in Emergent Biosolutions by 149.0% in the third quarter. Allianz Asset Management GmbH now owns 279,807 shares of the biopharmaceutical company’s stock worth $2,468,000 after acquiring an additional 167,423 shares in the last quarter. Federated Hermes Inc. increased its stake in Emergent Biosolutions by 43.6% during the third quarter. Federated Hermes Inc. now owns 401,258 shares of the biopharmaceutical company’s stock worth $3,539,000 after acquiring an additional 121,789 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in Emergent Biosolutions during the third quarter valued at approximately $393,000. Finally, New York State Common Retirement Fund raised its position in Emergent Biosolutions by 32.6% during the third quarter. New York State Common Retirement Fund now owns 522,004 shares of the biopharmaceutical company’s stock valued at $4,604,000 after purchasing an additional 128,429 shares during the period. Institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.